Current experimental gene therapy approaches for Parkinson's disease (PD) and dementia with Lewy bodies (DLB) include the use of viral vectors expressing antiapoptosis genes, neurotrophic factors and dopaminergic system enzymes. However, since increasing evidence favors a role for a-synuclein accumulation in the pathogenesis of these disorders, an alternative therapy might require the transfer of genes that might block a-synuclein accumulation. b-Synuclein, the nonamyloidogenic homologue of a-synuclein, has recently been identified as a potential candidate. Thus, in vivo transfer of genes encoding b-synuclein might provide a novel approach to the development of experimental treatments for PD and DLB. To assess this possibility and to better understand the mechanisms involved, a lentiviral vector expressing human (h) b-synuclein (lenti-b-synuclein) was tested in a transgenic (tg) mouse model of ha-synuclein aggregation. This study showed that unilateral intracerebral injection of lenti-b-synuclein reduced the formation of hasynuclein inclusions and the accumulation of ha-synuclein in synapses and ameliorated the neurodegenerative alterations in the tg mice. Both in vivo and in vitro coimmunoprecipitation and immunoblot experiments show that the mechanisms of b-synuclein neuroprotection involve binding of this molecule to ha-synuclein and Akt, resulting in the decreased aggregation and accumulation of ha-synuclein in the synaptic membrane. Together, these data further support a role for b-synuclein in regulating the conformational state of a-synuclein and suggest that this gene transfer approach might have potential for the development of alternative therapies for PD and DLB.
Introduction
Disorders with Lewy body (LB) formation such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are leading causes of cognitive and motor dysfunction in the aging population. However, only a few treatment methods are currently available. In recent years, considerable progress has been made in developing new therapies for these neurodegenerative disorders utilizing gene transfer strategies. 1 Since nigral dopaminergic loss is a common substrate for the neurological deficits in patients with these disorders, 2 most gene therapy approaches have been directed at protecting or rescuing neurons of the nigral-striatal (NS) pathway with vectors expressing antiapoptotic factors, neurotrophic agents and enzymes relevant to this circuitry. 1 However, it might be necessary to develop alternative gene therapy approaches in view of increasing evidence that favors a potential role for abnormal aggregation of a-synuclein in the central nervous system (CNS) as one of the central mechanisms involved in the pathogenesis of PD and DLB.
3-5 a-Synuclein is capable of selfaggregating to form both oligomers and polymers. [6] [7] [8] Toxic oligomers form protofibrils that can potentially damage the cell membrane and promote neurodegeneration. 9, 10 While in PD a-synuclein accumulation occurs primarily in the striatal nigral system, in DLB a-synuclein also accumulates in the neocortex and hippocampus.
In familial forms of parkinsonism, mutations accelerate aggregation 11, 12 and toxic conversion of a-synuclein. 13, 14 In sporadic forms of PD and DLB it is less clear what triggers a-synuclein aggregation; however, recent studies suggest that interactions between environmental factors promoting oxidative stress and genetic polymorphisms 15 might trigger a shift in the balance between factors promoting and blocking a-synuclein aggregation. 16 Therefore, an alternative therapy for PD and DLB might require the transfer of genes that might block the pathological aggregation of a-synuclein.
1 Among them, three potential candidates have been recently identified, namely b-synuclein, Parkin and heat-shock proteins (Hsp). 1, 17 b-Synuclein belongs to a larger family of synaptic proteins that includes a-synuclein and g-synuclein. 18 b-Synuclein is an abundant synaptic protein originally identified as PNP14 in the bovine brain. 19, 20 The most significant difference between the synucleins is that b-synuclein lacks the majority of the hydrophobic nonamyloid component (NAC) domain. 21 This highly amyloidogenic region is responsible for the self-aggregating capacity of a-synuclein. 21, 22 In contrast to asynuclein, b-synuclein does not aggregate under stress conditions or form insoluble oligomers and is capable of blocking a-synuclein aggregation both in vivo and in vitro. 21 At a critical ratio, b-synuclein might regulate the state of aggregation of a-synuclein; therefore alterations in this molecule might be associated with PD and DLB. 21 Remarkably, recent studies support this possibility by showing that levels of b-synuclein were decreased in brain regions selectively affected in DLB, such as the superior temporal cortex, the cingulate and substantia nigra (SN). 23 Taken together, these studies suggest that in vivo transfer of genes encoding for b-synuclein might oppose the deleterious effects of a-synuclein and possibly provide a novel strategy in the development of experimental treatments for PD and DLB. To assess this possibility and to better understand the mechanisms involved, a lentiviral vector expressing human (h) b-synuclein (lenti-b-synuclein) was prepared and tested in a transgenic (tg) model of DLB where a-synuclein accumulation was abundant in the neocortex and hippocampus. This approach was favored over other viral vectors because lentiviral vectors have been shown to efficiently transduce cells of the CNS and are not cytotoxic. [24] [25] [26] Furthermore, expression of the therapeutic product can theoretically be sustained for the life span of the animal. Lenti-b-synuclein reduces the neuronal accumulation of ha-synuclein and ameliorates the synaptic alterations in tg mice
Results

Expression
To assess the potential effects of b-synuclein in reducing ha-synuclein accumulation in vivo, ha-synuclein tg mice that develop inclusion bodies, synaptic loss and dopaminergic deficits 27 received an intracerebral injection with a lentiviral vector expressing either b-synuclein or GFP. Immunocytochemical analysis demonstrated that ha-synuclein tg mice injected with lenti-b-synuclein showed a considerable reduction in the accumulation of ha-synuclein in the neuronal cell bodies and in the formation of inclusion bodies in the neocortex (Figure 2a , b, e, f) and hippocampus (Figure 2i, j) , when compared to ha-synuclein tg mice treated with lenti-GFP (Figure 2c, d , g, h, k, l) or heat-inactivated lenti-b-synuclein (data not shown). Transgenic mice injected with lenti-b-synuclein (Figure 2m ) displayed significantly lower levels of ha-synuclein positive inclusions ipsilateral to the site of injection in both the neocortex and hippocampus, whereas contralateral to the injection, levels are comparable to lenti-GFP-treated tg mice (Figure 2n ). Double immunocytochemical studies (Figure 3a -d) confirmed these observations and showed that compared to vector controls (Figure 3c ), transduced neurons expressing high levels of lenti-b-synuclein displayed reduced accumulation of ha-synuclein (Figure 3d ). In neurons of the treated mice where both synucleins were coexpressed, hasynuclein was identified as discrete, granular aggregates Under physiological conditions a-synuclein is localized primarily to the presynaptic boutons 28 and in LBD and in the tg mice, increased accumulation of hasynuclein in the synapses is associated with functional deficits and synapse loss. 21 To ascertain the effects of lenti-b-synuclein treatment on ha-synuclein accumulation in the nerve terminals, double immunolabeling studies with antibodies against the presynaptic terminal marker synaptophysin and ha-synuclein were performed. Confocal imaging of double-labeled sections showed that in comparison to ha-synuclein tg mice injected with lenti-GFP (Figure 3g ), those that were injected with lenti-b-synuclein displayed decreased accumulation of ha-synuclein in synaptophysin-immunoreactive nerve terminals in the neocortex ( Figure 3h ) and hippocampus (data not shown). Consistent with these findings, image analysis showed that while in lenti-GFP or vector control-treated tg mice, approximately 70% of the synapses displayed intense transgene-derived ha-synuclein immunoreactivity, in mice treated with lenti-b-synuclein the proportion was reduced to 25% 
Lenti-b-synuclein reduces membrane translocation of ha-synuclein and promotes Akt activation
Since it is possible that abnormal accumulation of a-synuclein in synapses and neuronal cell bodies is associated with increased translocation of a-synuclein from the soluble to the insoluble fraction, we performed WB analysis with the cytosolic and particulate fractions of tg mice treated with lenti-b-synuclein. As expected, most of the ha-synuclein monomeric form was present in the cytosolic fraction (Figure 4a Reduction of ha-synuclein oligomers and monomers in the particulate fraction of brain homogenates of tg mice treated with lenti-b-synuclein corresponds to an increase in monomers in the cytosolic fraction. These studies suggest that b-synuclein might interact with a-synuclein, preventing its abnormal accumulation and membrane translocation. To investigate this possibility, immunoprecipitation studies were performed. This analysis showed that ha-synuclein was coimmunoprecipitated with b-synuclein in the brains of tg mice treated with lentib-synuclein but not in mice treated with the lenti-GFP vector control (Figure 4d ). To further verify these findings in an independent model system, B103 neuroblastoma cells transfected with ha-synuclein were treated with lenti-b-synuclein or lenti-GFP. Consistent with previous studies, 21 (Figure 4d ), immunoprecipitation experiments with the transfected cell lines followed by WB showed that ha-synuclein was coimmunoprecipitated with b-synuclein (Figure 5f ). Taken together, these results are consistent with the known capacity of b-synuclein to act as a chaperone molecule 29 and suggests that the protective effects of b-synuclein might be related to its ability to bind other molecules. Among them, recent in vitro studies have shown that b-synuclein binding to Akt stabilizes this molecule, resulting in its activation. This increased activity promotes neurite outgrowth and protects neurons from the neurotoxic effects of ha-synuclein. 30 Consistent with this possibility, WB analysis of the brains of tg mice treated with the lentiviral vectors showed that compared to lenti-GFP control, in mice treated with lentib-synuclein the levels of phospho (p) Akt, an activated form of this kinase, were higher ( Figure 6 ). Taken together, these results indicate that b-synuclein might protect against the neurotoxic effects of a-synuclein via activation of Akt signaling.
Discussion
The present study showed that b-synuclein gene transfer into a tg mouse model of PD and DLB resulted in decreased accumulation of ha-synuclein in synapses and neuronal cell bodies and ameliorated the neurodegenerative alterations associated with this process. To the best of our knowledge, this is the first study to use an antiaggregation gene therapy approach for the experimental treatment of these synucleopathies. These results are consistent with in vivo studies in tg mice showing that overexpression of b-synuclein (under the control of the thy-1 promoter) reduced the neurotoxic effects of a-synuclein. 21 These findings also support in vitro studies showing that b-synuclein inhibited the conversion of A53T a-synuclein protofibrils to fibrils 31 and reduced the formation of a-synuclein aggregates. 21, 32 Several mechanisms might be at play, including the possibility that bsynuclein might block further aggregation by preventing interactions of a-synuclein with fatty acids in the membrane, favoring the a-helix rather than the b-pleated conformation of a-synuclein. 33 In support of this, previous studies have demonstrated that a-and bsynuclein coimmunoprecipitate in double-transfected model systems 21, 34 and the present study showed that b-synuclein gene transfer reduced ha-synuclein oligomerization and abnormal accumulation of insoluble aggregates in the plasma membrane. Furthermore, both in the brains of tg mice as well as in the in vitro model system, b-synuclein coimmunoprecipitates with ha-synuclein, suggesting that interactions between these two Thus, a-synuclein may exist in at least two different structural forms: a cytosolic unfolded form and a membrane-bound form with a stable a-helical structure. 35, 36 It has been proposed that the membrane-bound form might have a higher tendency to form aggregates than the cytosolic form and might seed the aggregation of the cytosolic a-synuclein. 35, 37 The precise mechanisms involved in this process are not completely clear; however, some studies have proposed that this might be related to the high content of polyunsaturated fatty acids in the neuronal plasma membrane.
38,39 a-Synuclein has several fatty acid binding domains and the association of these with other molecules of a-synuclein promotes aggregation. 38 Thus, it is possible that the binding of b-synuclein to a-synuclein in the cytoplasm might block aggregation by inhibiting translocation of a-synuclein into the plasma membrane and interactions with fatty acids.
Alternatively, b-synuclein might decrease a-synuclein aggregation and neurotoxicity through indirect mechanisms, including regulation of signaling pathways that promote neuronal survival and synaptic plasticity.
Among them, the present study showed in tg mice lenti-b-synuclein treatment increased the activity of Akt, a signaling molecule that promotes neuroprotection. 40 Furthermore, recent studies in transfected neurons have shown that lenti-b-synuclein protects from the combined neurotoxic effects of ha-synuclein and rotenone by increasing the activation state of Akt. 30 The mechanisms of neuroprotection appear to be independent of upstream effects such as phosphatidylinositol 3-kinase (PI3-K) and phosphoinositide-dependent kinase (PDK)-1 and involve direct binding of b-synuclein to Akt, resulting in increased stability of the kinase and phosphorylation of downstream signaling molecules such as glycogen synthase kinase 3b (GSK3b) 30 and p53. 41 In regard to the latter signaling pathway, a recent study showed that b-synuclein protects from the toxic effects of 6-hydroxydopamine by decreasing the expression of the proapoptotic gene p53. 41 The mechanisms linking the effects of b-synuclein to the Akt and p53 signaling pathways are not completely clear. However, recent studies have shown that p53 expression and activity are regulated by Mdm2, 42 an oncoprotein that under normal conditions is restricted to the cytoplasm but when phosphorylated by activated Akt is translocated to the nucleus. In the nucleus, phosphorylated Mdm2 binds p53, inhibiting its apoptotic activity and promoting cell survival. 42 Taken together, these studies suggest that b-synuclein-mediated activation of the Akt signaling pathway might induce phosphorylation of, among other targets, Mdm2, promoting neuroprotection against toxins by inactivating p53.
Consequently, the development of new treatments for PD and DLB might require not only promoting regeneration of the dopaminergic system but also preventing further damage mediated by the accumulation of the a-synuclein neurotoxic species. Transfer of neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF) into the CNS of acute models of parkinsonism (ie 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine [MPTP], 6-hydroxydopamine) utilizing lentiviral vectors have recently been proposed as an alternative therapeutic approach for rescuing degenerating neurons and promoting regeneration of the NS system. 2, 43 The present study further supports the usefulness of this strategy and extends the validity of this approach in a tg mouse model of PD and DLB by showing that gene transfer therapy might also be utilized to reduce accumulation of neurotoxic a-synuclein in the brain.
In summary, these data further support a role for b-synuclein in regulating the conformational state of a-synuclein and suggest that this antiaggregation gene transfer approach might have potential for the development of alternative therapies for PD and DLB.
Materials and methods
Cell culture and medium
Rat neuroblastoma B103 cells were maintained in DMEM with 10% fetal calf serum (FCS) with sodium pyruvate and gentamicin. They were stably transfected with the mammalian expression vector pCEP4 (Invitrogen, Carlsbad, CA, USA) containing the ha-synuclein cDNA using Lipofectamine according to the manufacturer's protocol (Gibco/BRL, Grand Island, NY, USA) as previously Compared to tg mice treated with the control lenti-GFP, tg mice treated with lenti-b-synuclein displayed a two-fold increase in pAkt (Ser473) immunoreactivity, whereas there is no significant difference in tAkt immunoreactivity. *Significant difference compared to ha-synuclein tg mice treated with lenti-GFP (Po0.05, one-way ANOVA post hoc Dunnett's).
b-Synuclein gene transfer in PD/DLB M Hashimoto et al described. 44 This line was selected because overexpression of ha-synuclein in these cells results in abnormal accumulation of ha-synuclein oligomers in the neuronal cell bodies, reduced neurite plasticity and neurodegeneration. 44 
Lentiviral vector production
Vector plasmids were constructed for the production of third-generation lentiviral vectors that expressed the b-synuclein gene. The human cytomegalovirus (CMV) promoter was used to drive expression of the transgenes (Figure 1a) . Vector plasmids were also constructed expressing the enhanced GFP. Additional control experiments were performed with an empty lenti vector control. All vectors used the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) 3 0 to the transgene. We produced lentiviral vectors using a fourplasmid transfection system, as previously described. 45 Briefly, 293T cells were transfected with vector and packaging plasmids, the supernatants were collected and vectors were concentrated by centrifugation. The lentiviral vector titers were estimated by measuring the amount of HIV p24 gag antigen with an ELISA kit (Perkin-Elmer, Wellesley, MA, USA) (100 000 transducing units (TU) per nanogram of p24).
Generation and transduction of stably transfected cell lines
The B103 neuroblastoma cells, vector transfected and ha-synuclein transfected as previously described, 44 were grown in six-well plates at 50% confluence and were incubated with either lenti-b-synuclein or lenti-GFP (each at 1.0 Â 10 7 TU) in 10% FCS for 24 h at 371C, 5% CO 2 . The cells were then washed with phosphatebuffered saline (PBS) and incubated in DMEM with 10% FCS for an additional 4 days. The efficiency of transduction of lenti-GFP was more than 90%. Finally, cells were harvested in lysis buffer and used for immunoblot analysis. For immunocytochemistry, cells were cultured on coverslips until 50% confluence and treated as described above, fixed in 4% paraformaldehyde (PFA) for 20 min, and blocked overnight at 41C in 10% FCS and 5% bovine serum albumin (BSA).
In vitro immunoblot (Western blot) analysis
For the detection of ha-and b-synuclein in vitro, transduced cells (1.0 ng p24/cell) were lysed in cell lysis buffer plus protease inhibitors (Completet mini, Roche Biochemicals, Indianapolis, IN, USA). The lysates were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% Tris-acetate polyacrylamide gel (NuPAGEt, Invitrogen). Immunoblots were performed with primary antibodies against a-synuclein (Syn-1, 1:1000, Transduction Laboratories, San Diego, CA, USA) or b-synuclein (1:1000, Chemicon, Temecula, CA, USA) and a secondary goat anti-mouse or rabbit IgG tagged with horseradish peroxidase (HRP, 1:5000, 2 h, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), visualized by enhanced chemiluminescence (ECL, Perkin-Elmer) and analyzed with the VersaDoc gel imaging system (BioRad, Hercules, CA, USA).
Transgenic mouse lines and intracerebral injections of lentiviral vectors
For this study, mice overexpressing ha-synuclein from the platelet-derived growth factor b (PDGF-b) promoter (Line D) were utilized. This model was selected because mice from this line develop ha-synuclein immunoreactive inclusions distributed through the neocortex and hippocampus similar to what has been described in DLB. [46] [47] [48] A total of 48 ha-synuclein tg mice from line D (12 months old) were injected with 3 ml of the lentiviral preparations (1.5 Â 10 7 TU) into the temporal cortex and hippocampus. Briefly, as previously described, 45 mice were placed under anesthesia on a Koft stereotaxic apparatus and coordinates (AP -1.5 mm, lateral 1 mm, depth 2 mm) were determined as per the Franklin and Paxinos Atlas. The lentiviral vectors were delivered using a 5 ml Hamilton syringe connected to a hydraulic system to inject the solution at a rate of 0.5 ml every 2 min. To allow diffusion of the solution into the brain tissue, the needle was left for an additional 5 min after the completion of the injection. Mice received unilateral injections (right side) to allow comparisons against the contralateral side, with either lenti-b-synuclein (n ¼ 24), heat-inactivated lenti-b-synuclein (n ¼ 6), lenti-GFP (n ¼ 10) or vehicle alone (n ¼ 10). Mice survived for 4 weeks after the lentiviral injection. Following NIH guidelines for the humane treatment of animals, mice were anesthetized with chloral hydrate and flushperfused transcardially with 0.9% saline. Brains and peripheral tissues were removed and divided sagitally. The right hemibrain was postfixed in phosphatebuffered 4% PFA (pH 7.4) at 41C for 48 h for neuropathological analysis, while the left hemibrain was snapfrozen and stored at À701C for subsequent RNA and protein analysis.
RNA analysis
Total RNA was isolated from snap-frozen tissues using the TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). The following 32 P-labeled antisense riboprobes were used to identify specific mRNAs (protected nucleotides (GenBank accession number)): a-synuclein (nt 210-475 (No. L08850)); b-synuclein (nt 235-459 (No. S69965)); and murine actin (nt 480-559 (No. M18194) of mouse actin mRNA). Levels of specific RNAs were determined by RPA, as previously described. 49 Dried gels were exposed to Biomax s film (Kodak, Rochester, NY, USA) and signals were quantitated with a PhosphorImager SF (Molecular Dynamics, Sunnyvale, CA, USA) using the ImageQuant software and expressed as integrated pixel intensities over defined volumes. Final values were expressed as ratios of (specific signalbackground)/(actin signal-background) to correct for differences in RNA content and loading across samples.
In vivo immunoblot (Western blot) analysis
For detection of ha-synuclein in the brain, homogenates were separated into cytosolic and particulate fractions. 27 A measure of 12 mg of each fraction per mouse was loaded onto 10% SDS-PAGE gels, followed by transfer onto Immobilon membranes. These were then incubated with the anti-a-synuclein antibody (Syn-1, 1:1000, Transduction Laboratories) 21 and a secondary goat anti-mouse tagged with HRP (1:5000, 2 h, Santa Cruz Biotechnology, Coimmunoprecipitation of ha-synuclein with b-synuclein in transduced cells and tg mice
Coimmunoprecipitation assays were performed as previously described with minor modifications. 21 Briefly, cell extracts (200 mg) of either cytosolic or particulate fractions were diluted with 2 Â lysis buffer (1 Â lysis buffer: 1% Triton-X, 10% glycerol, 50 mM HEPES (pH 7.4), 140 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM phenyl-methyl-sulfonylfluoride, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 1 mM dithiothreitol) and precleared with protein G-sepharose for 30 min on ice. The samples were then incubated with either pre-immune serum or anti-b-synuclein serum overnight at 41C, followed by incubation with protein G-sepharose for 2 h. The immune complexes were then washed three times with the lysis buffer. The samples were then heated in the SDS sample buffer for 5 min and subjected to immunoblot analysis and visualization with ECL (Perkin-Elmer) on the VersaDoc system (BioRad).
Immunoblot analysis of Akt expression in mice treated with lenti-b-synuclein. Immunoblot analysis was performed as previously described. 30 Briefly, tg mouse brain homogenates were prepared, solubilized in lysis buffer (1% Triton X-100, 10% glycerol, 50 mM HEPES, pH 7.4, 140 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 20 mM b-glycerophosphate, and proteinase inhibitor cocktails), and centrifuged for 10 min at 14 000 rpm. The supernatant (20 mg) was then resolved by SDS-PAGE and electroblotted onto nitrocellulose membrane (Schleicher & Schunell, Keene, NH, USA). The membranes were blocked with Tris-buffered saline (TBS; 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2% NP-40, 0.2% Tween-20) containing 3% skim milk or BSA, followed by incubation with primary antibodies against pAkt (Ser473, 1:1000, Cell Signaling Technology, Beverley, MA, USA) or total (t) Akt (88-10, 1:1000, Calbiochem, San Diego, CA, USA) in TBS. After washing with TBS, the membranes were analyzed with ECL (Perkin-Elmer) on the VersaDoc gel imaging system (BioRad).
Immunocytochemical and neuropathological analyses
Immunocytochemical analysis for ha-synuclein was performed in serially sectioned, free-floating, blindcoded vibratome sections from tg and nontg mice treated with lenti-b-synuclein and control vectors. 27 Sections were incubated overnight at 41C with an anti-hasynuclein antibody (72-10, 1:500, affinity purified rabbit polyclonal), 27 followed by biotinylated goat anti-rabbit IgG (1:100, Vector Laboratories, Inc., Burlingame, CA, USA), Avidin D-HRP (1:200, ABC Elite, Vector), and reacted with diaminobenzidine tetrahydrochloride (DAB) containing 0.001% H 2 O 2 . Sections were analyzed with the Quantimet 570C (Leica) in order to determine the number of ha-synuclein immunoreactive inclusions in the neocortex. For each case, three sections were analyzed and the results were averaged and expressed as numbers per sq mm.
To determine efficiency of transduction, double-labeling experiments with b-synuclein and the neuronal marker NeuN (1:5000, Chemicon) were performed, as previously described. 21 To determine the relationship between ha-synuclein immunolabeled-inclusions and bsynuclein immunoreactive neurons, 40 mm-thick vibratome sections were immunolabeled with the rabbit polyclonal antibodies against ha-synuclein (72-10, 1:5000, affinity purified polyclonal) 27 and b-synuclein (1:100, Chemicon). The ha-synuclein immunoreactive structures were detected with the Tyramide Signal Amplificationt-Direct (Red) system (1:100, NEN Life Sciences, Boston, MA, USA) while b-synuclein was detected with the goat anti-rabbit fluorescein isothiocyanate (FITC) antibody (1:75, Vector). This system allows the simultaneous detection of signals from antibodies from the same species. To determine if b-synuclein gene transfer ameliorated the neurodegenerative alterations associated with the expression of ha-synuclein, sections were double-immunostained with a polyclonal antibody against ha-synuclein (72-10, 1:100, affinity purified rabbit) and a monoclonal antibody against synaptophysin (SY38, 1:25, Chemicon), followed by a mixture of horse anti-mouse FITC tagged secondary antibody (1:75, Vector) to detect synaptophysin and a goat anti-rabbit Texas Red tagged secondary antibody (1:75, Vector) to detect ha-synuclein. For each case, sections were immunolabeled in duplicate and analyzed with the laser confocal scanning microscope (LSCM) and NIH Image 1.43 software to calculate the percent area of the neuropil covered by synaptophysin-immunoreactive terminals in the neocortex. 50 For each case, three sections were analyzed, and for each section four serial optical sections (2 mm thick) were obtained. In order to confirm the specificity of the primary antibodies, control experiments were performed where sections were incubated overnight in the absence of primary antibody (deleted), with the primary antibody preadsorbed for 48 h with 20-fold excess of the corresponding peptide or with pre-immune serum.
All sections were processed simultaneously under the same conditions and experiments were performed twice in order to assess the reproducibility of results. Sections were imaged with a Zeiss 63X (N.A. 1.4) objective on an Axiovert 35 microscope (Zeiss, Germany) with an attached MRC1024 LSCM system (BioRad, Wattford, UK). 27 
Statistical analysis
All in vivo and in vitro experiments were conducted in triplicate on blind-coded samples. After the results were obtained, the code was broken and data were analyzed with the StatView 5.0 program (SAS Institute, Inc., NC, USA). Differences among means were assessed by oneway ANOVA followed by post hoc Dunnett's or TukeyKramer as indicated. Correlation studies were carried out by simple regression analysis. The null hypothesis was rejected at the 0.05 level.
